ClinicalTrials.gg
RecruitingNCT07303777Updated Apr 28, 2026

Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis

A Phase 2 interventional study of ABP-745 Dose A and Placebo in Atherosclerosis Cardiovascular Disease, ASCVD and ASCVD Management, sponsored by Atom Therapeutics Co., Ltd. Recruiting at 33 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Atom Therapeutics Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies in Atherosclerosis with a site in China — 36 open to participants now, 48 under way, 11 of them phase 3. Atherosclerosis · China.

Planned enrollment
37th of 79
200 · median 200
Started
2026
with 14 others
Phase 2
6 of 113
4 open now
Primary completion
2028-01
later than 34 of 47 live
Registered
98th of 113
by date

Among the 113 studies in Atherosclerosis with a site in China, this one is the 37th largest by planned enrollment of the 79 interventional ones that give a count, is one of 15 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 34 of the 47 other live ones, and was the 98th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

36 of the 113 studies in Atherosclerosis with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Atherosclerosis with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with ASCVD. The primary efficacy measurement will be assessed at 52W of treatment.

03

Conditions studied

  • Atherosclerosis Cardiovascular Disease
  • ASCVD
  • ASCVD Management

Browse trials for

Keywords

  • ASCVD
  • ABP-745
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Unless otherwise specified, subjects must meet all of the following criteria at screening:

  • Diagnosed with coronary at herosclerosis, and coronary angiography.
  • Male or female at 18-75 years of age (inclusive).
  • Weight ≥40 kg.
  • Currently using any oral lipid-lowering therapy.
  • Able to understand and willing to sign an ICF and comply with study requirements.
  • A woman or man of agreeing to use medically approved methods from the screening until 3 months after the last study dose.

Exclusion criteria

Exclusion Criteria:

Unless otherwise specified, subjects are excluded from the study if any of the following criteria is met:

  • History of stroke within the past 6 months.
  • Uncontrolled arrhythmia within 3 months prior to screening.
  • Evidence of any active or suspected cancer within 3 years prior to the screening.
  • Having undergone any major surgery within 3 months prior to the screening or planning to undergo any major surgery during the study.
  • Presence or suspicion of ongoing of any serious infection.
  • (HIV) infection.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Placebo comparator
    Placebo group

    Existing lipid-lowering maintenance medications unchanged.

    Drug: Placebo

  • Experimental
    ABP-745 Dose A

    Existing lipid-lowering maintenance medications unchanged.

    Drug: ABP-745 Dose A

  • Experimental
    ABP-745 Dose B

    Existing lipid-lowering maintenance medications unchanged.

    Drug: ABP-745 Dose B

  • Experimental
    ABP-745 Dose C

    Existing lipid-lowering maintenance medications unchanged.

    Drug: ABP-745 Dose C

Interventions

  • ABP-745 Dose A - tablets (PO), low dose , QD

  • DrugPlacebo

    ABP-745 placebo - tablets (PO), non-active,QD

  • ABP-745 Dose B - tablets (PO), Midum dose, QD

  • ABP-745 Dose C - tablets (PO), High dose, QD

06

What researchers measure

Primary outcomes

  1. Change from the baseline in percent atheroma volume (PAV)

    Time frame: 52 weeks after treatment

Secondary outcomes

  1. Change from the baseline in percent atheroma volume (PAV)

    Time frame: 24 weeks after treatment

  2. Incidence of treatment-emergent adverse events (Safety and Tolerability) TEAEs and SAEs, and clinically significant changes in physical examination, vital signs, safety laboratory tests, and 12-lead ECG.

    Time frame: up to 14 days post the last dose of study drug

07

Study locations

1 of 33 sites recruiting
  • Cardiovascular Research Foundation of Southern California
    Beverly Hills, California 90210, United States
    Not yet recruiting
    • Ronald P. Karlsberg · ContactKarlsberg@cvmg.com · (310) 278-3400
    • Ronald P. Karlsberg · Principal investigator
  • Cardiovascular Institute of San Diego INC
    San Diego, California 91911, United States
    Not yet recruiting
    • Milind M. Parikh, M.D. · ContactMilind.Parikh@cvisd.com · 619-616-2100
    • Milind Parikh, M.D. · Principal investigator
  • The Lundquist Institute
    Torrance, California 90502, United States
    Not yet recruiting
    • Matthew Budoff, M.D. · Contactmbudoff@lundquist.org · (424) 201-3000
    • Matthew Budoff, M.D. · Principal investigator
  • Washington University School of Medicine, St.louis
    St Louis, Missouri 63130, United States
    Not yet recruiting
    • Farhan M. Katchi, M.D. · Contactkatchif@wustl.edu · 314-362-1291
    • Farhan M. Katchi, M.D. · Principal investigator
  • NovaTrails
    Newcastle, New South Wales 2290, Australia
    Not yet recruiting
  • University of the Sunshine Coast Clinical Trials Unit - Morayfield
    Morayfield, Queensland 4506, Australia
    Not yet recruiting
    • Chris Moller, M.D. · Contact
    • Chris Moller, M.D. · Principal investigator
  • Core Research Group Pty Ltd
    Brisbane, Australia
    Not yet recruiting
    • Colquhoun David, M.D. · Principal investigator
  • UniSC Clinical Trials (Brisbane)
    Brisbane, Australia
    Not yet recruiting
    • Nsahai Sahai, M.D. · Contactnsahai@usc.edu.au
    • Nsahai Sahai, M.D. · Principal investigator
  • Cognivus
    Wahroonga, Australia
    Not yet recruiting
    • Elizabeth Shaw, MBBS · Principal investigator
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, China
    Not yet recruiting
    • Ping Wang · Principal investigator
  • Peking Union Medical College Hospital
    Beijing, China
    Not yet recruiting
    • Zhenyu Liu · Principal investigator
  • Peking University First Hospital
    Beijing, China
    Not yet recruiting
    • Yan Zhang · Principal investigator
  • Xuanwu Hospital Capital Medical University
    Beijing, China
    Not yet recruiting
    • Chunlin Yin · Principal investigator
  • Dalian Second Hospital
    Dalian, China
    Not yet recruiting
    • Xin Zhao · Principal investigator
  • Guangdong Province Hospital
    Guangzhou, China
    Not yet recruiting
    • Jiyan Chen · Principal investigator
  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
    Hangzhou, China
    Not yet recruiting
    • Guosheng Fu · Principal investigator
  • The First Affiliated Hospital of Zhejiang University school of medicine
    Hangzhou, China
    Not yet recruiting
    • Xiaogang Guo · Principal investigator
  • Zhejiang Provincial People's Hospital
    Hangzhou, China
    Not yet recruiting
    • Lihong Wang · Principal investigator
  • Jinan Central Hospital
    Jinan, China
    Not yet recruiting
    • Guohai Su · Principal investigator
  • Jiangsu Province Hospital
    Nanjing, China
    Not yet recruiting
    • Chunjian Li · Principal investigator
  • Nanjing Drum Tower Hospital
    Nanjing, China
    Not yet recruiting
    • Biao Xu · Principal investigator
  • Huashan Hospital Fudan University
    Shanghai, China
    Not yet recruiting
    • Jian Li · Principal investigator
  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, China
    Not yet recruiting
    • Jun Bu · Principal investigator
  • Shanghai General Hospital
    Shanghai, China
    Not yet recruiting
    • Shaowen Liu · Principal investigator
  • The Zhongshan Hospital Affiliated to Fudan University
    Shanghai, China
    Recruiting
    • Junbo Ge, M.D. · Principal investigator
  • The First Affiliated Hospital of Soochow University
    Suzhou, China
    Not yet recruiting
    • Tingbo Jiang · Principal investigator
  • Tianjin General Hospital
    Tianjin, China
    Not yet recruiting
    • Qing Yang · Principal investigator
  • Renmin Hospital of Wuhan University
    Wuhan, China
    Not yet recruiting
    • Xiaoyan Li · Principal investigator
  • Wuxi People's Hospital
    Wuxi, China
    Not yet recruiting
    • Ruxing Wang · Principal investigator
  • Shaanxi Provincial People's Hospital
    Xi'an, China
    Not yet recruiting
    • Junkui Wang · Principal investigator
  • The First Affiliated Hospital of Xian Jiaotong University
    Xi'an, China
    Not yet recruiting
    • Zuyi Yuan · Principal investigator
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, China
    Not yet recruiting
    • Jie Deng · Principal investigator
  • The Affiliated Hospital of Xuzhou Medical College
    Xuzhou, China
    Not yet recruiting
    • Dengfeng Pan · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — There is no such demand at present.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2028, 21 months after the start.

Of 46 phase 2 interventional studies under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Dec 26, 2025
StartActual
Apr 23, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Apr 2028
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07303777
Lead sponsor
Atom Therapeutics Co., Ltd
Responsible party
Sponsor
First posted
Dec 26, 2025
Start date
Apr 23, 2026
Primary completion
Jan 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Apr 28, 2026

Study contacts

Qiang Shi
Contact
qiang.shi@atombp.com
86+ 19117302212

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABP-745

Start the discussion